Clinical Trials
Eyepoint
The purpose of this research study is to learn how well EYP-1901 works compared with current standard of care treatment for wet AMD, which is an injection into the eye called EYLEA®.
Overview
The investigational therapy being tested in this study is EYP-1901. The purpose of this research study is to learn how well EYP-1901 works compared with current standard of care treatment for wet AMD, which is an injection into the eye called EYLEA®.
EYP-1901 is an insert that is placed inside the eye using a needle and is designed to slowly dissolve over time, allowing the controlled release of a medication called Vorolanib.
EYP-1901 is an experimental treatment. Vascular endothelial growth factor (VEGF) and Platelet-derived growth factor (PDGF) are the proteins found in the eyes that by various actions cause Wet AMD. Vorolanib works by blocking these proteins.
The study runs for approximately 2 years and would require participants to attend Cerulea on a monthly basis for study assessments and/or treatment appointments.
For further information about this study please contact the Clinical Trials Research Centre on (03) 9929 8076 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
A/Prof Sanj Wickremasinghe
The investigational therapy being tested in this study is EYP-1901. The purpose of this research study is to learn how well EYP-1901 works compared with current standard of care treatment for wet AMD, which is an injection into the eye called EYLEA®.
EYP-1901 is an insert that is placed inside the eye using a needle and is designed to slowly dissolve over time, allowing the controlled release of a medication called Vorolanib.
EYP-1901 is an experimental treatment. Vascular endothelial growth factor (VEGF) and Platelet-derived growth factor (PDGF) are the proteins found in the eyes that by various actions cause Wet AMD. Vorolanib works by blocking these proteins.
The study runs for approximately 2 years and would require participants to attend Cerulea on a monthly basis for study assessments and/or treatment appointments.
For further information about this study please contact the Clinical Trials Research Centre on (03) 9929 8076 or email info@ceruleaclinicaltrials.org.au
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.